CME credits: 0.50

Valid until: 24-09-2020

Claim your CME credit at https://reachmd.com/programs/cme/learner-pathway-moderate-severe-ad-expert-mentoring-challenging-patient-cases-care-team-forum/10967/

“I begged my doctor for something else – there had to be something else,” Pam.

For over 50 years, Pam suffered with uncontrolled moderate-to-severe atopic dermatitis (AD). She experienced the evolution of treatment strategies over the course of the several decades, trying everything from topicals to off-label targeted systemic agents. She was willing to try anything to make the unbearable itch go away. In this roundtable discussion, we brought Pam and her dermatologist to discuss AD with a multidisciplinary physician panel. Together they weigh in on experimental and newly approved therapies, management strategies, impact on quality-of-life, and shared decision-making techniques, all supplemented by Pam’s unfiltered, down-to-earth reality check of what life with AD and all these drugs really feels like.

CME credits: 0.50

Valid until: 23-09-2020

Claim your CME credit at https://reachmd.com/programs/cme/advancedmetastatic-nsclc-treatment-advancements-for-patients-without-targetable-activating-mutations/10880/

NSCLC is a highly active research area and its treatment is rapidly evolving. The algorithm for the treatment of advanced NSCLC has become increasingly complex as new therapies are being developed, including advances in the treatment of patients without targetable activating mutations. Studies evaluating immune checkpoint inhibitors as single agents and in combination with chemotherapy as first-line therapy for patients with advanced NSCLC without targetable activating mutations have been reported. Clinicians need to be familiar with these data and the evolving treatment landscape so they are prepared to optimally select and sequence treatment options for these patients.

Through real-world clinical cases, the expert panel will evaluate the most recent clinical data and provide evidence-based updates and expert insights on the discussion points. Discussion will include immunotherapy and combination regimens for the initial treatment of patients with advanced NSCLC without targetable activating mutations, and how the experts discerned the best treatment approaches based upon unique disease and patient characteristics.

CME credits: 0.25

Valid until: 20-09-2020

Claim your CME credit at https://reachmd.com/programs/cme/cases-in-influenza-management-aggressive-treatment-in-older-adults-with-comorbidities/10835/

Seasonal influenza can be debilitating in most individuals, but in high-risk populations, such as older patients and those with certain comorbidities, it can contribute to increased morbidity and mortality. Fortunately, with the addition of a recently approved polymerase acidic endonuclease inhibitor to the stable of neuraminidase inhibitors, there’s a growing opportunity to personalize care and improve outcomes for these high-risk patients.

Join Dr. Nicola Hanania and Dr. John Russell as they evaluate the impact of influenza on at-risk and high-risk individuals as well as the integration of these newer and emerging influenza agents into personalized treatment plans.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

CME credits: 0.25

Valid until: 20-09-2020

Claim your CME credit at https://reachmd.com/programs/cme/cases-in-influenza-management-right-interventions-to-achieve-earlier-return-to-action/10834/

Whether it’s due to healthy students simply not worrying about getting the flu or awareness gaps regarding the vaccine’s effectiveness, the challenges that come with enforcing the influenza vaccination on a college campus can be plenty. To help address this common challenge, this activity will review the case of a college student that demonstrates the impact of influenza on these at-risk individuals and communities.

Since the launch of the activity, the US FDA has approved a new indication for baloxavir marboxil to include the treatment of acute, uncomplicated influenza in people 12 years of age and older who have been symptomatic for no more than 48 hours, who are otherwise healthy, or who are at high risk of developing flu-related complications.

CME credits: 0.25

Valid until: 30-06-2021

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/viewpoints-on-managing-dr-addressing-moderate-to-severe-npdr/10905/

Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

CME credits: 0.25

Valid until: 30-04-2021

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/viewpoints-on-cases-in-diabetic-retinopathy-what-the-optometrist-needs-to-know/10904/

A paradigm shift is occurring for the management of nonproliferative diabetic retinopathy, with new evidence demonstrating that patients with moderately-severe to severe nonproliferative diabetic retinopathy can benefit from anti-VEGF treatment. Join Dr. Mark Dunbar and Dr. Jay Haynie as they discuss the evidence for this evolution and what optometrists need to know to protect the vision of their patients with diabetic eye disease.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

CME credits: 0.25

Valid until: 31-12-2020

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/diabetic-retinopathy-understanding-the-impact-on-patient-lives-and-the-need-for-timely-diagnosis/10898/

Even though diabetic retinopathy is the leading cause of blindness among U.S. adults, a substantial number of patients with diabetes are not receiving routine eye exams and are at risk of vision loss. Making matters worse is the fact that many patients with diabetes remain unaware that this disease can affect their vision. That’s why this discussion with a panel of expert faculty will examine what it means to be proactive in promoting vision screening and minimizing the risk for vision loss with appropriate early treatment in these patients.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

CME credits: 0.25

Valid until: 31-12-2020

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/seeing-eye-to-eye-case-series-on-treatment-strategies-for-diabetic-retinopathy-pdr-dme/10906/

As the management of diabetic retinopathy and diabetic macular edema continues to evolve, those devoted to retinal care continue to learn about what can be done now to better manage and individualize treatment for patients with these conditions. This discussion between Dr. Sharon Solomon and Dr. Charles Wykoff will review the current and emerging treatment paradigms for managing diabetic retinopathy and diabetic macular edema and considerations for applying them into clinical practice.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

CME credits: 0.25

Valid until: 31-12-2020

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/viewpoints-on-managing-dr-addressing-moderate-to-severe-npdr/10905/

Even though the prevalence of diabetes continues to rise globally, the good news is that there are emerging treatment options for diabetic eye diseases like nonproliferative diabetic retinopathy. Join Dr. David Brown and Dr. Rishi Singh as they review the recent evidence behind one of these options: anti-VEGF inhibitors.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.

CME credits: 0.25

Valid until: 31-12-2020

Claim your CME credit at https://reachmd.com/national-eye-institute/nei-blindness-prevention-initiative/viewpoints-on-cases-in-diabetic-retinopathy-what-the-optometrist-needs-to-know/10904/

A paradigm shift is occurring for the management of nonproliferative diabetic retinopathy, with new evidence demonstrating that patients with moderately-severe to severe nonproliferative diabetic retinopathy can benefit from anti-VEGF treatment. Join Dr. Mark Dunbar and Dr. Jay Haynie as they discuss the evidence for this evolution and what optometrists need to know to protect the vision of their patients with diabetic eye disease.

Vision loss caused by diabetic retinopathy can have a significant impact on a patient's quality of life. This activity emphasizes more assertive action in clinical practice for patient with diabetes. The acronym ASSERT-D is a reminder to Assess and Screen for Eye health and Refer or Treat patients with Diabetes.